UnknownPhase 3NCT05462587
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
Studying Leukocyte adhesion deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AUG Therapeutics
- Principal Investigator
- David Deyle, MD, D.D.SMayo Clinic
- Intervention
- AVTX-803 (L-Fucose)(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05462587 on ClinicalTrials.govOther trials for Leukocyte adhesion deficiency
Additional recruiting or active studies for the same condition.